Phase 2Completed
A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
- Sponsor
- Unity Biotechnology, Inc. (Industry)
- Enrolment
- 183 enrolled
- Conditions
- Osteoarthritis, Knee
- Interventions
- UBX0101; Placebo
- Ages
- adults, older adults
- Registry
- NCT04129944
From the registry
A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
Primary outcomes
- Change From Baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale (WOMAC-A) Score in Patients Receiving a Single Dose of UBX0101 Versus Those Receiving Placebo